Last updated May 16, 2026
Audience guide · demographic
GLP-1 for Teens (12-17) in 2026
FDA-approved for 12+ — pediatric obesity pathway with strict criteria
Verified by James Cole, MD, FACOGHow we review
Wegovy and Saxenda are FDA-approved for adolescents 12-17 with obesity. This is a serious pediatric medical pathway with rigorous eligibility criteria, mandatory lifestyle program documentation, and growth monitoring requirements.
Who this guide is for
- Profile
- Adolescents 12-17 with severe obesity (BMI ≥95th percentile + adult BMI ≥30 equivalent). ~14M US teens have obesity.
- Common goals
- Weight management for severe obesity, prevent progression to T2D and cardiovascular complications, address obesity-related comorbidities (sleep apnea, NAFLD).
- Constraints
- Pediatric endocrinologist oversight required. Insurance approval requires documented 6-month lifestyle program failure. Growth + nutritional monitoring mandatory. Mental health screening required.
- Coverage reality
- Commercial plans cover Wegovy for 12+ with pediatric obesity PA. Medicaid in 13 weight-loss-covered states extends to teens. Tricare covers with medical necessity. Saxenda has the longest pediatric track record.
Ranked for Teens (12-17)
Fit scores reflect this audience’s constraints — not raw clinical efficacy. A drug can be 9/10 overall yet 4/10 for a specific audience because of coverage or cost.
- 1Wegovy9.0/10 fit
FDA-approved semaglutide for chronic weight management
FDA-approved for adolescents 12+ (2022). STEP TEENS trial showed 16.1% body weight reduction at 68 weeks in teens.
Heads up: Pediatric endocrinology referral typically required for prescription.
- 2Zepbound5.5/10 fit
FDA-approved tirzepatide for weight loss
Not FDA-approved for teens. Pediatric trials ongoing (SURMOUNT-AYO). Off-label use discouraged.
Heads up: Avoid until pediatric trial readout. Wegovy is the indicated pathway.
- 3Ozempic5.0/10 fit
Semaglutide approved for type 2 diabetes
FDA-approved for T2D 10+ years old (Ozempic specifically not approved for teen T2D — but Trulicity is).
Heads up: For teen T2D, Trulicity is the FDA-approved option, not Ozempic.
- 4Mounjaro4.5/10 fit
Tirzepatide for type 2 diabetes
Not FDA-approved for teens. No pediatric T2D data.
Heads up: Not appropriate for adolescent use until trial data emerges.
- 5Hims & Hers Weight Loss2.0/10 fit
Compounded semaglutide via telehealth
Hims requires age 18+ per their telehealth policy. Compounded use in minors is medically inappropriate without pediatric specialist oversight.
Heads up: Do not use compounded telehealth for adolescents. Period.
Key considerations
- Pediatric endocrinology oversight required
GLP-1 use in teens should be managed by a pediatric endocrinologist or obesity medicine specialist — not a general pediatrician or telehealth service. Growth velocity, sexual maturation, and bone mineralization must be monitored.
- Mental health screening mandatory
FDA labels emphasize psychiatric symptom monitoring in adolescents. Pre-screen for depression, anxiety, eating disorders, suicidal ideation. Continue screening every 3 months during treatment.
- Family-based behavioral intervention is the foundation
GLP-1s in teens work best when paired with structured family-based behavioral programs (Bright Bodies, MEND). Medication alone has worse long-term outcomes than medication + program.
Frequently asked questions
Is Wegovy safe for my teen?
In the STEP TEENS trial (12-17 year olds with BMI ≥95th percentile), safety profile was similar to adults. Most common side effects: nausea (42%), vomiting (29%), diarrhea (23%). Serious adverse events were rare. Growth was not negatively affected over 68 weeks.
What's the youngest age for GLP-1?
Wegovy and Saxenda are FDA-approved starting at age 12. Trulicity (dulaglutide) is FDA-approved for type 2 diabetes starting at age 10. Younger ages require off-label use with specialist oversight.
Will my teen need to stay on this forever?
Probably not at the adult treatment paradigm. Most pediatric obesity protocols use GLP-1s as a bridge to durable lifestyle change during adolescence, then attempt discontinuation post-puberty when growth has stabilized. Long-term pediatric data still developing.
Audience guides synthesize coverage data, clinical recommendations, and demographic-specific constraints. Always verify your specific situation with a licensed prescriber.
Last verified: May 16, 2026